Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Protagonist Therapeutics Trying To Close In On Key Technical Benchmark

On Friday, Protagonist Therapeutics received an upgrade to its Relative Strength (RS) Rating, from 68 to 76.

IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of at least 80 in the early stages of their moves. See if Protagonist Therapeutics can continue to rebound and clear that threshold.

Can You Really Time The Stock Market?

Protagonist Therapeutics is building a consolidation with a 48.89 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.

Earnings grew 350% last quarter, up from 0% in the prior report. Revenue also increased, from -100% to 184%.

Protagonist Therapeutics earns the No. 5 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the No. 1-ranked stock within the group.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.